" class="no-js "lang="en-US"> Full-Life Technologies - Medtech Alert
Friday, October 03, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Full-Life | Pharmtech Focus

Full-Life Technologies

About Full-Life Technologies

Full-Life Technologies
Full-Life technologies limited (“Full-Life”) is a fully integrated global Nuclear Health company headquartered in Shanghai with operations in Europe. We seek to own the entire value chain for radio-ligand production, research, development and commercialization in order to deliver clinical impact for patients. Our core platform seeks to attack the two core issues that exist in radiopharmaceuticals today: 1) the ability to produce in high quality and quantity radioisotope to meeting tomorrow’s needs and 2) innovative translational and biology research platform targeting the radio-pharma treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with demonstrated track record in life-science company building as well as radio-isotope research and clinical development. We seek to unleash the power of half-life in order to bring the potential of a Full-Life to patients across the world.

Related Story

Industry News

 Focus-X Therapeutics Successfully Reached an Acquisition Agreement with Full-Life Technologies | PTF

Focus-X Therapeutics Successfully Reached an Acquisition Agreement with Full-Life Technologies

December 2 2022

Focus-X Therapeutics, a nuclide drug company that was invested in and incubated by Viva Biotech, […]

Industry News

 Full-Life Technologies to Acquire Focus-X Therapeutics

Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline

November 29 2022

Full-Life Technologies, a fully integrated global radiotherapeutics company, today announced an agreement to acquire New Jersey-based […]

Appointments

 Full-Life Technologies Deepens Radioisotope Technology Expertise with Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board | Pharmtech Focus

Full-Life Technologies Deepens Radioisotope Technology Expertise with Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board

August 10 2022

Full-Life Technologies Co., Ltd. (“Full-Life”) today announced two key appointments to its Radioisotope Technology leadership team […]

Diseases

 Full-Life Technologies Completes $37 Million (USD) Series A Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Radiotechnology Production Platform | Pharmtech Focus

Full-Life Technologies Completes $37 Million (USD) Series A Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Radiotechnology Production Platform

May 26 2022

Full-Life Technologies (“Full-Life”) today announced it completed a $37 million (USD) Series A financing round to advance […]